Liquid Biopsy Market On Target to Reach $3,805 Million by 2023, at a CAGR of 28.9% | Trovagene Inc., Guardant Health Inc

Rise in demand for non-invasive, safe procedures, increase in prevalence of cancer, and benefits over traditional test procedures would drive the growth of the global liquid biopsy industry. The report offers detailed analyses of the key winning strategies, market dynamics, market size & estimations, top investment pockets, and competitive landscape.

Download Detailed COVID-19 Impact Sample Report at @ https://www.alliedmarketresearch.com/request-for-customization/1891?reqfor=covid

The global liquid biopsy market garnered $830 million in 2017 and is expected to reach $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023.

COVID-19 scenario-

1) Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing on essential medical devices production including ventilators and diagnostics.

2) However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.

3) Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.

Increasing use of non-invasive, safe procedures, rising incidence of cancer, and advantages associated with liquid biopsy drive the growth of the market. However, lack of awareness in emerging and underdeveloped economies hampers the market growth. On the other hand, use of this technique for early detection & diagnosis of cancer as well as characterization of new lesions would create new opportunities for the market players.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1891

Circulating tumor cell segment to maintain lion's share during the forecast period

The circulating tumor cell segment generated more than two-thirds of the total market share in 2017, owing to its ability to help understand the metastatic process and cancer development. This segment would maintain its lion's share by 2023. However, the extracellular vesicle (EV) segment is expected to register the fastest CAGR of 30.4% from 2017 to 2023 due to rise in adoption of EV analysis for disease diagnosis and therapeutic monitoring in cancer patients. The report also analyzes circulating tumor DNA and other biomarkers.

Kits & reagents segment to remain dominant by 2023

The kits & reagents segment contributed nearly 85% of the total market share in 2017 and is expected to dominate throughout the forecast period. This is attributed to the advent of novel liquid biopsy reagents and kits, which are used to carry out circulating biomarker analysis, size selection, target enrichment, and other functions. However, the platforms and instruments segment would grow at the fastest CAGR of 29.8% from 2017 to 2023, owing to their utility in automating the process of liquid biopsy testing and ability to offer holistic turnkey solutions. The service segment is expected to grow at a steady rate during the forecast period.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1891

Lung cancer segment to contribute major revenue share throughout the forecast period

The lung cancer segment contributed nearly one-third share of the total market revenue in 2017, owing to the prevalence of non-small-cell lung cancer (NSCLC). This segment would remain dominant during the forecast period. The prostate cancer segment would grow at the highest CAGR of 31.8% from 2017 to 2023 due to the rise in commercialization of prostate cancer tests, especially AdnaTest Prostate Cancer Panel AR-V7 (Qiagen). The report also analyzes breast, colorectal, liver, and other cancer types.

Hospitals & laboratories segment to remain dominant by 2023

Hospitals & laboratories segment held the major market share, contributing more than 90% of the total revenue in 2017. This is due to the rise in prevalence of cancer, increase in cancer recurrence among patients, and extensive coverage & applications of liquid biopsy tests in medical settings. However, government & academic research centers segment would register the highest CAGR of 30.1% from 2017 to 2023, owing to surge in R&D activities and precision in results.

Asia-Pacific to register the fastest growth

Large population base, rise in disposable income, increase in prevalence of cancer, and surge in R&D activities and healthcare facilities have enabled the Asia-Pacific region to grow at the fastest CAGR of 30.3% from 2017 to 2023. On the other hand, North America contributed more than one-third of the total market share in 2017, owing to upsurge in prevalence of cancer, preference for minimally invasive procedures, and ease in availability and accessibility of liquid biopsy testing.

To know more about the report, visit the website at @ https://www.alliedmarketresearch.com/liquid-biopsy-market

The Major Key Players Are:

Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG , Bio-Rad Laboratories Inc., Myriad Genetics , Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.

Similar Reports:

Cosmetic Laser Market : https://www.einnews.com/pr_news/528467146/cosmetic-laser-market-is-estimated-to-experience-a-notable-rise-in-the-span-of-coming-years

Medical Display Market : https://www.einnews.com/pr_news/528732449/medical-display-market-to-look-at-the-biggest-trends-hitting-the-industry-over-the-coming-12-months

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.